aap Implantate AG / aap receives U.S. notice of allowance for key patent relating to LOQTEQ® . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) an developer, manufacturer and marketer of innovative solutions for trauma products, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the latest and currently marketed core technology of its locking and compression plate system LOQTEQ®.
Bruke Seyoum Alemu, Chief Executive Officer, stated: "This is a major milestone for our company and an important recognition of the truly novel nature of our LOQTEQ® technology. aap's current wide product offering based on this unique technology platform is already successfully launched in more than 15 key international markets. This patent allowance validates our efforts in developing innovative technologies and products that help our clients to gain clinical as well as economical value. Further, this patent will greatly accelerate our efforts to set our footprint in the US and strengthen our competitive position as our entire trauma portfolio including LOQTEQ® is already FDA approved. Importantly, the allowed claims underline our philosophy that is based on our, close customer collaboration on the one side and innovative product engineering and development on the other side."
This notice represents a significant advancement in aap's strategy to build a strong IP-portfolio around LOQTEQ®. Today aap has four patent families and a wide range of patents related to the LOQTEQ® technology.
"This patent allowance by the USPTO is not only another important milestone in protecting the commercial potential of LOQTEQ®, but along with our recent patent granted to our silver coating technology, demonstrates our strong overall commitment to protecting the innovation and commercial opportunity of our core trauma product portfolio." said Bruke Seyoum Alemu, Chief Executive Officer of aap, said.
About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
aapThe issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
